SecBot SecBot

MPLT

MapLight Therapeutics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001770069 Biotech & Drug Discovery
$7.66 −0.31 (−3.89%)
Oct 26 4:00 PM ET · prev $7.97
Market cap
$534.4M
Small cap
Consensus
Buy
85% Buy or better · 20 analysts
Median target
$25.00
+226% · range $13.00–43.00
1 year
−58.2%
from $18.34 · Oct 27
30 days
−26.7%
from $10.45
52-week range
$7.66–39.80
at the low
Avg volume 20D
379.8K
shares / day
Short interest
🔒 Subscribers only
Insider net
−$8.2M
1 buyer · 6 sellers · since Jul 15
New fund stakes
1
Q2 2026 13F · 0 exits
Filing reports
29
analyzed by SecBot
SecBot read MIXED 9 reports · 90 days
Balance 2 bearish · 1 bullish · 6 neutral oldest → newest, height = score
Avg score ·High conf. 7/9
Strongest BEARISH CEO Christopher Kroeger and CAO/Interim CFO Jonathan Gillis sold a combined $678K in open-market sales on…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    1 insider bought $148.7K at an average $9.52. 6 insiders sold $8.4M. Price is 20% below their cost.

  • InstitutionsBULLISH

    Q2 2026: 13 added (1 new), 7 trimmed or exited. Largest new: Capital World Investors $14.9M.

  • AnalystsBULLISH

    17 of 20 rate it Buy or better. Every target is above the price.

  • TrendDOWNTREND

    29% below its 50-day average. New closing low $7.66 on Oct 26.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$14.9M
in new stakes
FundMoveSharesValue
PRICE T ROWE ASSOCIATES INC /MD/DOUBLED1,422,935$51.0M
STATE STREET CORPDOUBLED852,150$30.5M
FMR LLCDOUBLED823,556$29.5M
Capital World InvestorsNEW415,730$14.9M
BNP Paribas Asset Management Holding S.A.TRIM170,862$6.1M
Freestone Grove Partners LPTRIM168,912$6.1M
UBS Group AGTRIM122,028$4.4M
LAZARD ASSET MANAGEMENT LLCTRIM80,082$2.9M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

20 analysts
Buy 85% rate it Buy or better
Strong Buy7Buy10Hold3Sell0Strong Sell0
12-month targets · 13 analysts

Price is below the lowest target. Median implies +226%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Oct 6, 2026Guggenheim
INITIATE
INITIATENeutral
Aug 31, 2026Needham
MAINTAIN
MAINTAINBuy
Aug 10, 2026UBS
DOWNGRADE
DOWNGRADENeutral
Jul 28, 2026Canaccord Genuity
MAINTAIN
MAINTAINBuy
Jul 28, 2026Morgan Stanley
DOWNGRADE
DOWNGRADEEqual-Weight
Jul 28, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$148.7K
bought · 1 insider
$8.4M
sold · 6 insiders
−19.5%
vs their $9.52 cost
DateInsiderTypeValue
Oct 15, 2026
GILLIS JONATHAN
CAO and Interim CFO
SELL$82.1K
Oct 15, 2026
Kroeger Christopher A.
Chief Executive Officer
SELL$595.4K
Oct 15, 2026
Hanson Kristopher
General Counsel
SELL$72.9K
Oct 15, 2026
Lillie James Woodruff
Chief Scientific Officer
SELL$93.0K
Oct 15, 2026
Kreitzer Anatol
Chief Discovery Officer
SELL$96.0K
Oct 15, 2026
Foff Erin Pennock
Chief Medical Officer
SELL$124.1K
Sep 16, 2026
Hanson Kristopher
General Counsel
SELL$192.7K
Aug 17, 2026
Kroeger Christopher A.
Chief Executive Officer
AWARD23,145 sh

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 16, 2026 SEC
CEO Christopher Kroeger and CAO/Interim CFO Jonathan Gillis sold a combined $678K in open-market sales on October 15…
CLUSTER — Impact 4/10
Oct 15, 2026 SEC
Jonathan Gillis, an officer of MapLight Therapeutics, filed a Form 144 notice of intent to sell 10,167 shares of…
144 — Impact 2/10
Oct 15, 2026 SEC
Christopher A. Kroeger, an officer of MapLight Therapeutics, filed a Form 144 notice of intent to sell 73,691 shares…
144 — Impact 2/10
Oct 15, 2026 Insider
GILLIS JONATHAN sold 10,167 shares
CAO and Interim CFO @ $8.08 ($82.1K)
Oct 15, 2026 Insider
Kroeger Christopher A. sold 73,691 shares
Chief Executive Officer @ $8.08 ($595.4K)
Oct 15, 2026 Insider
Hanson Kristopher sold 9,020 shares
General Counsel @ $8.08 ($72.9K)
Oct 6, 2026 Other
MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics
Award honors foundational discoveries in optogenetics and circuit mapping
Jun 30, 2026 Inst.
PRICE T ROWE ASSOCIATES — DOUBLED
1,422,935 shares ($51.0M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 6, 2026
Press release
MapLight Therapeutics Celebrates Co-Founder Dr. Karl Deisseroth on Receipt of 2026 Nobel Prize in Physiology or Medicine for the Development of Optogenetics
Award honors foundational discoveries in optogenetics and circuit mapping
Sep 9, 2026
Press release
MapLight Therapeutics to Participate in Upcoming Investor Conference
SAN FRANCISCO and BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its…
Sep 1, 2026
Earnings date
MPLT Q2 2026 Earnings Scheduled — 2026-09-01
Aug 25, 2026
Trial readout
Results Pending: ML-007C-MA BID (Phase 2) — Completed 82d ago
Trial: A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia Sponsor: MapLight…
Aug 11, 2026
Trial readout
Results Pending: ML-007C-MA BID (Phase 2) — Completed 68d ago
Trial: A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Inpatient Adults With Schizophrenia Sponsor: MapLight…

SecBot reports

29 filings · 2 press releases · 2 bullish · 5 bearish · 1 mixed · 21 neutral
All MPLT filing & press-release reports (31)